ALGS - CIK 0001799448
The table below shows Aligos Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $29.98M | $41.95M | $18.66M | $73.76M | $35.33M | $45.08M |
| Short-term investments | $24.93M | $57.15M | $104.28M | $64.10M | $39.59M | $49.46M |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $59.63M |
| $103.44M |
| $127.94M |
| $143.21M |
| $79.82M |
| $99.57M |
| Property, plant & equipment | $1.59M | $2.04M | $2.06M | $2.21M | $2.58M | $2.80M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $64.56M | $109.76M | $134.71M | $150.70M | $88.43M | $108.81M |
| Accounts payable | $7.64M | $4.65M | $3.94M | $4.46M | $2.74M | $6.82M |
| Total current liabilities | $23.32M | $21.99M | $20.27M | $18.95M | $20.96M | $23.56M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $32.77M | $37.93M | $32.84M | $34.25M | $38.33M | $41.58M |
| Retained earnings | -$665.24M | -$622.32M | -$590.78M | -$574.92M | -$535.86M | -$516.60M |
| Total equity | $31.79M | $71.83M | $101.87M | $116.44M | $50.10M | $67.23M |